HATTERSHEIM, Germany, July 3, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product ...

After blood vessel damage, effective blood clotting is essential to halt bleeding. However, this process is inefficient in some individuals due to hereditary factors. Hemophilia B, for example, ...

Idelvion (coagulation factor IX [recombinant], albumin fusion protein) is a prescription drug used to treat and help prevent bleeding episodes in people with hemophilia B. Idelvion is given as an ...

Hemophilia B causes a deficiency in factor IX, a protein necessary for blood clotting. Replacement factor IX therapy is the gold standard treatment, but novel and genetic therapies are showing promise ...

Hemophilia B, also known as Christmas disease, is a bleeding disorder. Its characteristic feature is a deficiency of clotting factor IX. This is a protein present in the blood that helps with ...

The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed. Patients with hemophilia, von Wille-brand's disease (VWD), or acquired inhibitors to ...

KING OF PRUSSIA, Pa., Dec. 7, 2025 /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the ...

Expanded indication would cover patients 12 years of age or younger, a population that comprises approximately one in three patients treated for hemophilia B in the United States "Approximately one ...

Hemophilia B is a genetic disorder that affects how well your blood clots. Treatment includes supplementing the protein factor IX, but new therapies may offer alternative ways to manage factor IX ...